

# Analysis Of Adenylate Cyclase 6 In K562 Cell Chemical Induced Megakaryocyte Differentiation

何秋億、李泰林

E-mail: 364829@mail.dyu.edu.tw

## ABSTRACT

Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder. Hematopoietic stem cell can replenish functional blood cell, like erythrocyte (red blood cell), platelet, leukocyte, plasma cell, lymphocyte, and macrophage. Patients suffer their lost in functional blood cell and the ratio of non-function cell increased. K562 cell was isolated from the pleural effusion of the leukemia patient and was used as a model cell line to study the relationship between the blood cell differentiation and signal transduction. In this report, three different inducers, huangqi (*Astragalus membranaceus*) extract, chemicals Hemin and HMBA were used to induce K562 cell differentiation and several cluster of differentiation (CD) marker were used to identify the cell lineage. Two megakaryocyte markers were up-regulated in these treatments. The CD61, a late marker, was highly expressed in HMBA treated cell and CD41, an earlier marker, was identified in huangqi treated cell. In former report, the Gi2 and Gs was induced by the HMBA administration. Since both G proteins affect their downstream effector adenylate cyclases (ADCYs), the ADCYs that could be participated in the pathway were examined by RT-PCR. The ADCY1 and ADCY6 were up-regulated in the HMBA-induced K562 cell. The ADCY1 is expressed mainly in the brain and the ubiquitous ADCY6 were cloned. The ADCY6 transfected cells were treated with three inducers, the data showed that all induced increased CD61 expression and huangqi and Hemin induced CD41 expression. The ADCY6 transfected cells increased CD61 expression. The results imply that the signal from inducers and ADCY6 may participate the megakaryocyte differentiation. The study suggested that K562 cells can change the signal pathway through the ADCY isoforms to alter cell differentiation. That may be used as the reference of the gene therapy of leukemia.

Keywords : K562 cell、HMBA、Megakaryocyte、Heterotrimeric G-protein、Adenylate cyclases

## Table of Contents

封面內頁 簽名頁 中文摘要.....	iii	英文摘
要.....	v	誌謝.....vii
目錄.....	ix	圖目錄.....xvi
錄.....	xvii	1. 前言.....
顧.....	3	2.1 幹細胞 (stem cells) 之介紹.....
血幹細胞 (hematopoietic stem cells, HSC) .....	4	2.2 造
) .....	5	2.3 慢性骨髓性血癌 (chronic myeloid leukemia, CML
細胞.....	5	2.3.1 慢性骨髓性血癌之成因.....
取物.....	6	2.4 人類慢性骨髓細胞株K562
亞甲基雙乙醯胺 (Hexamethylene bisacetamide, HMBA) .....	7	2.5.1 黃耆萃
究.....	7	2.5.2 血晶質 (Hemin) .....
元體G 蛋白與巨核細胞.....	8	2.5.3 六
2.8.1 6 號腺?酸環化? (ADCY6) .....	8	2.6 K562 和巨核細胞分化之研
胞.....	9	2.7 異三單元鳥嘌呤核?酸結合蛋白.....
刺激增加ADCY 活性.....	10	2.7.1 異三單
15 2.10 研究目的.....	10	2.8 腺?酸環化?之介紹.....
3.1 細胞培養.....	11	2.8.2 腺?酸環化? (ADCY) 與巨核細
3.1.1.1 K562 細胞株.....	12	2.9 異三單元體G-protein 與ADCY 活性.....
17 3.1.1.3 HEK-293T/17 細胞株.....	13	2.9.1 透過Gs
製.....	14	2.9.2 透過Gi 抑制ADCY 活性.....
左旋麩酸醯胺 (L-Glutamine) 之配製.....	15	3. 研究方法.....
製.....	17	3.1 細胞培養.....
K562 細胞培養基之配製.....	17	3.1.1 細胞株.....
製.....	17	3.1.1.1 K562 細胞株.....
20 3.1.2.7 HEK-293T / 17 細胞培養基之配製.....	17	3.1.1.2 HEL 細胞株.....
	20	3.1.1.3 HEK-293T/17 細胞株.....
	20	3.1.2 細胞培養試劑之配
	18	3.1.2.1 抗生素 (antibiotics) 之配製.....
	18	3.1.2.2 左
	18	3.1.2.3 丙酮酸鈉 (Sodium pyruvate) 之配
	19	3.1.2.4 胎牛血清 (Fetal Bovine Serum, FBS) 之預處理.....
	19	3.1.2.5
	19	3.1.2.6 HEL 細胞培養基之配
	20	3.1.2.7 HEK-293T / 17 細胞培養基之配製.....
	20	3.1.2.8

磷酸鹽緩衝液 ( Phosphate-buffered Saline, PBS ) 之配製.....	20	3.1.2.9 胰蛋白酶 ( Trypsin ) 之預處理.....	21
理.....	21	3.1.2.10 染劑.....	21
法.....	21	3.1.3 細胞培養方法.....	21
K562 與HEL 細胞繼代培養.....	21	3.1.3.1 細胞繼代培養.....	21
養.....	22	3.1.3.1.1 HEK-293T 細胞繼代培養.....	22
和HEL 細胞冷凍保存.....	22	3.1.3.2 細胞冷凍保存.....	22
存.....	23	3.1.3.2.1 K562 和HEL 細胞冷凍保存.....	22
試劑.....	23	3.1.3.2.2 HEK-293T 冷凍保存.....	23
( Astragalus membranaceus ) 萃取液之配製.....	23	3.2 細胞試驗材料與方法.....	23
製.....	24	3.2.1 細胞試驗試劑.....	23
製.....	24	3.2.1.1 誘導劑.....	23
聯苯胺 ( Benzidine ) 之配製.....	24	3.2.1.1.1 黃耆 ( Astragalus membranaceus ) 萃取液之配製.....	23
.....	25	3.2.1.1.2 血晶質 ( Hemin ) 之配製.....	23
細胞誘導.....	25	3.2.1.1.3 六亞甲基雙乙醯胺 ( hexamethylene bisacetamide, HMBA ) 之配製.....	24
.....	25	3.2.1.3 雙氧水 ( Hydrogen peroxide ) .....	25
Hemin 誘導條件.....	25	3.2.2 細胞誘導.....	25
HMBA 誘導條件.....	26	3.2.2.1 黃耆誘導條件.....	25
.....	26	3.2.2.2 Hemin 誘導條件.....	25
細胞轉染 ( transfection ) ..... .....	26	3.2.2.3 HMBA 誘導條件.....	26
K562 轉染.....	26	3.3 分子生物技術分析材料與方法.....	27
HEK-293 轉染.....	26	3.3.1 血癌細胞之總RNA 萃取.....	27
分子生物技術分析材料與方法.....	27	3.3.1.1 RNA 萃取試劑配製.....	27
RNA 萃取試劑配製.....	27	3.3.1.1.1 檸檬酸鈉 ( Sodium citrate ) 溶液之配製.....	27
檸檬酸鈉 ( Sodium citrate ) 溶液之配製.....	27	3.3.1.1.2 Sodium lauryl sarcosinate 溶液之配製.....	27
Sodium lauryl sarcosinate 溶液之配製.....	28	3.3.1.1.3 Solution D ( denaturing solution ) 溶液之配製.....	28
Solution D ( denaturing solution ) 溶液之配製.....	28	3.3.1.1.4 醋酸鈉 ( Sodium acetate ) 溶液之配製.....	28
醋酸鈉 ( Sodium acetate ) 溶液之配製.....	28	3.3.1.1.5 RNA 萃取液之配製.....	29
RNA 萃取液之配製.....	29	3.3.1.2 DEPC.H <sub>2</sub> O 之配製.....	29
DEPC.H <sub>2</sub> O 之配製.....	29	3.3.1.3 RNA 定量方法.....	30
DEPC-Ethonal 之配製.....	29	3.3.2 cDNA 之製備.....	30
RNA 定量方法.....	30	3.3.2.1 反轉錄引子 ( reverse transcriptional primer ) ..... .....	30
cDNA 之製備.....	30	3.3.2.2 以反轉錄反應合成第一股cDNA ( first-strain cDNA ) ..... .....	30
反轉錄引子 ( reverse transcriptional primer ) ..... .....	30	3.3.2.3 以聚合 $\gamma$ 連鎖反應 ( polymerase chain rection, PCR ) 確認第一股cDNA 之合成..... .....	31
以反轉錄反應合成第一股cDNA ( first-strain cDNA ) ..... .....	31	3.3.3 洋菜膠電泳 ( agarose gel electrophoresis ) ..... .....	31
以聚合 $\gamma$ 連鎖反應 ( polymerase chain rection, PCR ) 確認第一股cDNA 之合成..... .....	31	3.3.3.1 電泳緩衝液之配製.....	31
洋菜膠電泳 ( agarose gel electrophoresis ) ..... .....	31	3.3.3.1.1 EDTA 之配製.....	32
電泳緩衝液之配製.....	32	3.3.3.1.2 TBE 之配製.....	32
EDTA 之配製.....	32	3.3.3.1.3 洋菜膠之配製.....	32
TBE 之配製.....	32	3.3.3.2 洋菜膠之配製.....	32
洋菜膠之配製.....	32	3.3.3.3 電泳過程.....	32
電泳過程.....	32	3.3.4 目標基因表現量之分析.....	33
目標基因表現量之分析.....	33	3.3.4.1 血紅球蛋白 ( hemoglobin ) mRNA 表現量之分析..... .....	33
血紅球蛋白 ( hemoglobin ) mRNA 表現量之分析..... .....	33	3.3.4.2 巨核細胞 ( megakaryocyte ) 標記CD41 和CD61 mRNA 表現量之分析..... .....	33
巨核細胞 ( megakaryocyte ) 標記CD41 和CD61 mRNA 表現量之分析..... .....	33	3.3.4.3 單核細胞 ( monocyte ) 標記CD14 和CD68 mRNA 表現量之分析..... .....	34
單核細胞 ( monocyte ) 標記CD14 和CD68 mRNA 表現量之分析..... .....	34	3.3.4.4 顆粒細胞 ( granulocyte ) 標記CD13 和CD33 mRNA 表現量之分析..... .....	34
顆粒細胞 ( granulocyte ) 標記CD13 和CD33 mRNA 表現量之分析..... .....	34	3.3.4.5 ADCY mRNA 表現量之分析..... .....	34
ADCY mRNA 表現量之分析..... .....	34	3.3.5 選殖全長片段.....	34
選殖全長片段.....	34	3.3.5.1 K562 細胞中ADCY6 基因全長序列之選殖..... .....	35
K562 細胞中ADCY6 基因全長序列之選殖..... .....	35	3.3.5.2 回收洋菜瓊脂膠體中之DNA 片段..... .....	36
回收洋菜瓊脂膠體中之DNA 片段..... .....	36	3.3.5.3 insert DNA 預處理.....	36
insert DNA 預處理.....	36	3.3.6 小分子干擾RNA ( Small Interfering RNA, siRNA ) 之合成..... .....	37
小分子干擾RNA ( Small Interfering RNA, siRNA ) 之合成..... .....	37	3.3.6.1 siRNA 之增幅.....	37
siRNA 之增幅.....	37	3.3.6.2 以聚乙醯胺膠體電泳 ( polyacrylamide gel elephoresis, PAGE ) 分離出siRNA..... .....	37
以聚乙醯胺膠體電泳 ( polyacrylamide gel elephoresis, PAGE ) 分離出siRNA..... .....	37	3.3.6.2.1 過硫酸銨 ( ammonia persulfate, APS ) 之配製.....	37
過硫酸銨 ( ammonia persulfate, APS ) 之配製.....	37	3.3.6.2.2 聚乙醯胺膠體之配製.....	38
聚乙醯胺膠體之配製.....	38	3.3.6.2.3 電泳過程.....	38
電泳過程.....	38	3.3.6.2.4 回收聚乙醯胺膠體中之siRNA..... .....	38
回收聚乙醯胺膠體中之siRNA..... .....	38	3.3.7 構築表現載體和靜默載體.....	39
構築表現載體和靜默載體.....	39	3.3.7.1 表現載體預處理.....	39
表現載體預處理.....	39	3.3.7.2 靜默載體預處理.....	39
靜默載體預處理.....	39	3.3.7.3 ADCY6 全長片段之分離..... .....	40
ADCY6 全長片段之分離..... .....	40	3.3.7.4 shADCY6 和shLuciferase 片段之分離..... .....	40
shADCY6 和shLuciferase 片段之分離..... .....	40	3.3.8 微生物培養試劑.....	41
微生物培養試劑.....	41	3.3.8.1 Luria-Bertani ( LB ) Broth 之配製.....	41
Luria-Bertani ( LB ) Broth 之配製.....	41	3.3.8.2 Luria-Bertani Agar ( LA ) 之配製.....	41
Luria-Bertani Agar ( LA ) 之配製.....	41	3.3.8.3 Ampcillcin 之配製.....	42
Ampcillcin 之配製.....	42	3.3.8.4 Kanamycin 之配製.....	42
Kanamycin 之配製.....	42	3.3.9 轉型作用 ( transformation ) ..... .....	42
轉型作用 ( transformation ) ..... .....	42	3.3.9.1 菌種.....	42
菌種.....	42	3.3.9.2 熱休克轉型法 ( heat-shock transformation ) ..... .....	42
熱休克轉型法 ( heat-shock transformation ) ..... .....	42	3.3.10 微生物小量培養.....	43
微生物小量培養.....	43	3.3.11 質體小量製備.....	43
質體小量製備.....	43	3.3.12 微生物大量培養.....	44
微生物大量培養.....	44	4 結果.....	44
結果.....	46	4.1 誘導劑誘導K562 細胞分化各株系細胞.....	46
誘導劑誘導K562 細胞分化各株系細胞.....	46	4.1.1 K562 細胞分化後分析巨核細胞之標記.....	46
K562 細胞分化後分析巨核細胞之標記.....	46	4.1.2 K562	46

細胞分化後分析紅血細胞之標記.....	46	4.1.3 K562 細胞分化後分析顆粒細胞之標記.....	47
4.1.4 K562 細胞分化後分析單核細胞之標記.....	47	4.2 K562 細胞分化後分析ADCY1 ~ 9 mRNA 表現量.....	47
4.3 確認外源ADCY6 大量表現於K562 細胞.....	48	4.3.1 誘導大量表現ADCY6 之K562 細胞分化後分析巨核細胞之標記.....	49
4.3.2 誘導大量表現ADCY6 之K562 細胞分化後分析紅血細胞之標記.....	49	4.3.3 誘導大量表現ADCY6 之K562 細胞分化後分析顆粒細胞之標記.....	49
4.3.4 誘導大量表現ADCY6 之K562 細胞分化後分析單核細胞之標記.....	50	4.4 轉染ADCY6 靜默載體以抑制K562 細胞中ADCY6mRNA 之表現.....	50
5. 討論.....	52	6. 結論.....	56
參考文獻.....	106	附錄.....	117

## REFERENCES

- 1.Krupinski, J., Coussen, F., Bakalyar, H., Tang, W., Feinstein, P., Orth, K., Slaughter, C., Reed, R. and Gilman, A. (1989) Adenylyl cyclase amino acid sequence: possible channel- or transporter-like structure. *Science*, 244, 1558-1564.
- 2.Tang, W. and Gilman, A. (1995) Construction of a soluble adenylyl cyclase activated by Gs alpha and forskolin. *Science*, 268, 1769-1772.
- 3.Hurley, J.H. (1999) Structure, mechanism, and regulation of mammalian adenylyl cyclase. *The Journal of biological chemistry*, 274, 7599-7602.
- 4.Robison, G.A., Butcher, R.W. and Sutherland, E.W. (1968) Cyclic AMP. *Annual review of biochemistry*, 37, 149-174.
- 5.Gilman, A.G. (1987) G proteins: transducers of receptor-generated signals. *Annual review of biochemistry*, 56, 615-649.
- 6.Sunahara, R.K. and Taussig, R. (2002) Isoforms of mammalian adenylyl cyclase: multiplicities of signaling. *Molecular interventions*, 2, 168-184.
- 7.Smith, A.G. (2001) Embryo-derived stem cells: of mice and men. *Annual review of cell and developmental biology*, 17, 435-462.
- 8.Edwards, R.G. and Beard, H.K. (1997) Oocyte polarity and cell determination in early mammalian embryos. *Molecular human reproduction*, 3, 863-905.
- 9.Chen, J. (2011) Hematopoietic stem cell development, aging and functional failure. *International journal of hematology*, 94, 3-10.
- 10.Mikkola, H.K. and Orkin, S.H. (2006) The journey of developing hematopoietic stem cells. *Development*, 133, 3733-3744.
- 11.Wright, D.E., Wagers, A.J., Gulati, A.P., Johnson, F.L. and Weissman, I.L. (2001) Physiological migration of hematopoietic stem and progenitor cells. *Science*, 294, 1933-1936.
- 12.Adams, G.B., Alley, I.R., Chung, U.I., Chabner, K.T., Jeanson, N.T., Lo Celso, C., Marsters, E.S., Chen, M., Weinstein, L.S., Lin, C.P. et al. (2009) Haematopoietic stem cells depend on Galpha(s)-mediated signalling to engraft bone marrow. *Nature*, 459, 103-107.
- 13.Sawyers, C.L. (1999) Chronic myeloid leukemia. *The New England journal of medicine*, 340, 1330-1340.
- 14.Nowell PC, H.D. (1960) A minute chromosome in human chronic granulocytic leukemia. *Science*, 132, 1497.
- 15.Rowley, J.D. (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. *Nature*, 243, 290-293.
- 16.Arlin, Z.A., Silver, R.T. and Bennett, J.M. (1990) Blastic phase of chronic myeloid leukemia (bICML): a proposal for standardization of diagnostic and response criteria. *Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K.*, 4, 755-757.
- 17.Kurzrock, R. and Talpaz, M. (1991) The molecular pathology of chronic myelogenous leukaemia. *British journal of haematology*, 79 Suppl 1, 34-37.
- 18.Kurzrock, R., Kantarjian, H.M., Druker, B.J. and Talpaz, M. (2003) Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. *Annals of internal medicine*, 138, 819-830.
- 19.Van Etten, R.A. (1999) Cycling, stressed-out and nervous: cellular functions of c-Abl. *Trends in cell biology*, 9, 179-186.
- 20.Pluk, H., Dorey, K. and Superti-Furga, G. (2002) Autoinhibition of c-Abl. *Cell*, 108, 247-259.
- 21.Pendergast, A.M., Muller, A.J., Havlik, M.H., Clark, R., McCormick, F. and Witte, O.N. (1991) Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. *Proceedings of the National Academy of Sciences of the United States of America*, 88, 5927-5931.
- 22.Lozzio, C.B. and Lozzio, B.B. (1975) Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. *Blood*, 45, 321-334.
- 23.Koeffler, H.P. and Golde, D.W. (1980) Human myeloid leukemia cell lines: a review. *Blood*, 56, 344-350.
- 24.Jacquel, A., Herrant, M., Defamie, V., Belhacene, N., Colosetti, P., Marchetti, S., Legros, L., Deckert, M., Mari, B., Cassuto, J.P. et al. (2006) A survey of the signaling pathways involved in megakaryocytic differentiation of the human K562 leukemia cell line by molecular and c-DNA array analysis. *Oncogene*, 25, 781-794.
- 25.Kawasaki, N., Morimoto, K., Tanimoto, T. and Hayakawa, T. (1996) Control of hemoglobin synthesis in erythroid differentiating K562 cells. I. Role of iron in erythroid cell heme synthesis. *Archives of biochemistry and biophysics*, 328, 289-294.
- 26.Marie, J.P., Izaguirre, C.A., Civin, C.I., Mirro, J. and McCulloch, E.A. (1981) The presence within single K-562 cells of erythropoietic and granulopoietic differentiation markers. *Blood*, 58, 708-711.
- 27.Wang, M., Wang, L., Pan, X.J. and Zhang, H. (2012) Monocytic differentiation of K562 cells induced by proanthocyanidins from grape seeds. *Archives of pharmacal research*, 35, 129-135.
- 28.Cheng, X.D., Hou, C.H., Zhang, X.J., Xie, H.Y., Zhou, W.Y., Yang, L., Zhang, S.B. and Qian, R.L. (2004) Effects of Huangqi (Hex) on inducing cell differentiation and cell death in K562 and HEL cells. *Acta biochimica et biophysica Sinica*, 36, 211-217.
- 29.Rutherford, T.R., Clegg, J.B. and Weatherall, D.J. (1979) K562 human leukaemic cells synthesise embryonic haemoglobin in response to haemin. *Nature*, 280, 164-165.
- 30.Rutherford, T., Clegg, J.B., Higgs, D.R., Jones, R.W., Thompson, J. and Weatherall, D.J. (1981) Embryonic erythroid differentiation in the human leukemic cell line K562. *Proceedings of the National Academy of Sciences of the United States of America*, 78, 348-352.
- 31.Charnay, P. and Maniatis, T. (1983) Transcriptional regulation of globin gene expression in the human erythroid cell line K562. *Science*, 220, 1281-1283.
- 32.Kucukkaya, B., Arslan, D.O. and Kan, B. (2006) Role of G proteins and ERK activation in hemin-induced erythroid differentiation of K562 cells. *Life sciences*, 78, 1217-1224.
- 33.Reuben, R.C., Wife, R.L., Breslow, R., Rifkind, R.A. and Marks, P.A. (1976) A new group of potent inducers of differentiation in

murine erythroleukemia cells. *Proceedings of the National Academy of Sciences of the United States of America*, 73, 862-866. 34.Green, A.R., Rockman, S., DeLuca, E. and Begley, C.G. (1993) Induced myeloid differentiation of K562 cells with downregulation of erythroid and megakaryocytic transcription factors: a novel experimental model for hemopoietic lineage restriction. *Experimental hematology*, 21, 525-531. 35.Tetteroo, P.A., Massaro, F., Mulder, A., Schreuder-van Gelder, R. and von dem Borne, A.E. (1984) Megakaryoblastic differentiation of proerythroblastic K562 cell-line cells. *Leukemia research*, 8, 197-206. 36.Alitalo, R. (1990) Induced differentiation of K562 leukemia cells: a model for studies of gene expression in early megakaryoblasts. *Leukemia research*, 14, 501-514. 37.Milligan, G. and Kostenis, E. (2006) Heterotrimeric G-proteins: a short history. *British journal of pharmacology*, 147 Suppl 1, S46-55. 38.Brass, L.F., Laposata, M., Banga, H.S. and Rittenhouse, S.E. (1986) Regulation of the phosphoinositide hydrolysis pathway in thrombin-stimulated platelets by a pertussis toxin-sensitive guanine nucleotide-binding protein. Evaluation of its contribution to platelet activation and comparisons with the adenylyl cyclase inhibitory protein, Gi. *The Journal of biological chemistry*, 261, 16838-16847. 39.Lapetina, E.G., Reep, B. and Chang, K.J. (1986) Treatment of human platelets with trypsin, thrombin, or collagen inhibits the pertussis toxin-induced ADP-ribosylation of a 41-kDa protein. *Proceedings of the National Academy of Sciences of the United States of America*, 83, 5880-5883. 40.Williams, A.G., Woolkalis, M.J., Poncz, M., Manning, D.R., Gewirtz, A.M. and Brass, L.F. (1990) Identification of the pertussis toxin-sensitive G proteins in platelets, megakaryocytes, and human erythroleukemia cells. *Blood*, 76, 721-730. 41.Gagnon, A.W., Manning, D.R., Catani, L., Gewirtz, A., Poncz, M. and Brass, L.F. (1991) Identification of G $\alpha$  as a pertussis toxin-insensitive G protein in human platelets and megakaryocytes. *Blood*, 78, 1247-1253. 42.Nagata, Y., Oda, M., Nakata, H., Shozaki, Y., Kozasa, T. and Todokoro, K. (2001) A novel regulator of G-protein signaling bearing GAP activity for G $\alpha$  and G $\alpha$  in megakaryocytes. *Blood*, 97, 3051-3060. 43.Hurley, J.H. (1998) The adenylyl and guanylyl cyclase superfamily. *Current opinion in structural biology*, 8, 770-777. 44.Tang, W.J., Stanzel, M. and Gilman, A.G. (1995) Truncation and alanine-scanning mutants of type I adenylyl cyclase. *Biochemistry*, 34, 14563-14572. 45.Yan, S.Z., Huang, Z.H., Shaw, R.S. and Tang, W.J. (1997) The conserved asparagine and arginine are essential for catalysis of mammalian adenylyl cyclase. *The Journal of biological chemistry*, 272, 12342-12349. 46.Zamponi, G.W. and Snutch, T.P. (1998) Modulation of voltage-dependent calcium channels by G proteins. *Current opinion in neurobiology*, 8, 351-356. 47.Premont, R.T., Matsuoka, I., Mattei, M.G., Pouille, Y., Defer, N. and Hanoune, J. (1996) Identification and characterization of a widely expressed form of adenylyl cyclase. *The Journal of biological chemistry*, 271, 13900-13907. 48.Sunahara, R.K., Dessauer, C.W. and Gilman, A.G. (1996) Complexity and diversity of mammalian adenylyl cyclases. *Annual review of pharmacology and toxicology*, 36, 461-480. 49.Taussig, R., Iniguez-Lluhi, J.A. and Gilman, A.G. (1993) Inhibition of adenylyl cyclase by G $\alpha$ . *Science*, 261, 218-221. 50.Taussig, R., Tang, W.J., Hepler, J.R. and Gilman, A.G. (1994) Distinct patterns of bidirectional regulation of mammalian adenylyl cyclases. *The Journal of biological chemistry*, 269, 6093-6100. 51.Kozasa, T. and Gilman, A.G. (1995) Purification of recombinant G proteins from Sf9 cells by hexahistidine tagging of associated subunits. Characterization of  $\alpha$ 12 and inhibition of adenylyl cyclase by  $\alpha$ z. *The Journal of biological chemistry*, 270, 1734-1741. 52.Cooper, D.M., Karpen, J.W., Fagan, K.A. and Mons, N.E. (1998) Ca<sup>2+</sup>-sensitive adenylyl cyclases. *Advances in second messenger and phosphoprotein research*, 32, 23-51. 53.Chiono, M., Mahey, R., Tate, G. and Cooper, D.M. (1995) Capacitative Ca<sup>2+</sup> entry exclusively inhibits cAMP synthesis in C6-2B glioma cells. Evidence that physiologically evoked Ca<sup>2+</sup> entry regulates Ca<sup>2+</sup>-inhibitable adenylyl cyclase in non-excitabile cells. *The Journal of biological chemistry*, 270, 1149-1155. 54.Bayewitch, M.L., Avidor-Reiss, T., Levy, R., Pfeuffer, T., Nevo, I., Simonds, W.F. and Vogel, Z. (1998) Inhibition of adenylyl cyclase isoforms V and VI by various Gbetagamma subunits. *The FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 12, 1019-1025. 55.Ye, J.Y., Chan, G.C., Qiao, L., Lian, Q., Meng, F.Y., Luo, X.Q., Khachigian, L.M., Ma, M., Deng, R., Chen, J.L. et al. (2010) Platelet-derived growth factor enhances platelet recovery in a murine model of radiation-induced thrombocytopenia and reduces apoptosis in megakaryocytes via its receptors and the PI3-k/Akt pathway. *Haematologica*, 95, 1745-1753. 56.Cornejo, M.G., Mabalal, V., Sykes, S.M., Khandan, T., Lo Celso, C., Lopez, C.K., Rivera-Munoz, P., Rameau, P., Tothova, Z., Aster, J.C. et al. (2011) Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification. *Blood*, 118, 1264-1273. 57.Kostyak, J.C. and Naik, U.P. (2011) Calcium- and integrin-binding protein 1 regulates endomitosis and its interaction with Polo-like kinase 3 is enhanced in endomitotic Dami cells. *PloS one*, 6, e14513. 58.den Dekker, E., Gorter, G., Heemskerk, J.W. and Akkerman, J.W. (2002) Development of platelet inhibition by cAMP during megakaryocytopoiesis. *The Journal of biological chemistry*, 277, 29321-29329. 59.Sadana, R. and Dessauer, C.W. (2009) Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies. *Neuro-Signals*, 17, 5-22. 60.Tovey, S.C., Dedos, S.G., Taylor, E.J., Church, J.E. and Taylor, C.W. (2008) Selective coupling of type 6 adenylyl cyclase with type 2 IP3 receptors mediates direct sensitization of IP3 receptors by cAMP. *The Journal of cell biology*, 183, 297-311. 61.Gao, M.H., Tang, T., Guo, T., Miyanojima, A., Yajima, T., Pestonjamas, K., Feramisco, J.R. and Hammond, H.K. (2008) Adenylyl cyclase type VI increases Akt activity and phospholamban phosphorylation in cardiac myocytes. *The Journal of biological chemistry*, 283, 33527-33535. 62.Kehlenbach, R.H., Matthey, J. and Huttner, W.B. (1994) XL  $\alpha$ s is a new type of G protein. *Nature*, 372, 804-809. 63.Novotny, J. and Svoboda, P. (1998) The long (Gs( $\alpha$ )-L) and short (Gs( $\alpha$ )-S) variants of the stimulatory guanine nucleotide-binding protein. Do they behave in an identical way? *Journal of molecular endocrinology*, 20, 163-173. 64.Sunahara, R.K., Dessauer, C.W., Whisnant, R.E., Kleuss, C. and Gilman, A.G. (1997) Interaction of G $\alpha$  with the cytosolic domains of mammalian adenylyl cyclase. *The Journal of biological chemistry*, 272, 22265-22271. 65.Sprang, S.R. (1997) G protein mechanisms: insights from structural analysis. *Annual review of biochemistry*, 66, 639-678. 66.Tesmer, J.J., Sunahara, R.K., Gilman, A.G. and Sprang, S.R. (1997) Crystal structure of the catalytic domains of adenylyl cyclase in a complex with G $\alpha$ .GTP $\gamma$ S. *Science*, 278, 1907-1916. 67.Dessauer, C.W., Tesmer, J.J., Sprang, S.R. and Gilman, A.G. (1998) Identification of a G $\alpha$  binding site on type V adenylyl

cyclase. *The Journal of biological chemistry*, 273, 25831-25839. 68. Linder, M.E., Middleton, P., Hepler, J.R., Taussig, R., Gilman, A.G. and Mumby, S.M. (1993) Lipid modifications of G proteins: alpha subunits are palmitoylated. *Proceedings of the National Academy of Sciences of the United States of America*, 90, 3675-3679. 69. Melloni, E., Pontremoli, S., Michetti, M., Sacco, O., Cakiroglu, A.G., Jackson, J.F., Rifkind, R.A. and Marks, P.A. (1987) Protein kinase C activity and hexamethylenebisacetamide-induced erythroleukemia cell differentiation. *Proceedings of the National Academy of Sciences of the United States of America*, 84, 5282-5286. 70. Rutherford, T.R. and Weatherall, D.J. (1979) Deficient heme synthesis as the cause of noninducibility of hemoglobin synthesis in a Friend erythroleukemia cell line. *Cell*, 16, 415-423. 71. Legros, L., Bourcier, C., Jacquelin, A., Mahon, F.X., Cassuto, J.P., Auberger, P. and Pages, G. (2004) Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. *Blood*, 104, 495-501. 72. Liu, X., Wang, Y., Sun, Q., Yan, J., Huang, J., Zhu, S. and Yu, J. (2012) Identification of microRNA transcriptome involved in human natural killer cell activation. *Immunology letters*, 143, 208-217. 73. 涂慧珠. (2006) GNAS、Gi和Gq蛋白經由Huangqi、Hemin和HMBA誘導K562細胞分化中所扮演之角色. 大葉大學分子生物科技學系碩士班, 1-111. 74. 來國鈞. (2008) 不同型G蛋白在藥劑誘導K562細胞分化下所扮演調合者角色. 大葉大學分子生物科技學系碩士論文, 1-130. 75. Tabilio, A., Pelicci, P.G., Vinci, G., Mannoni, P., Civin, C.I., Vainchenker, W., Testa, U., Lipinski, M., Rochant, H. and Breton-Gorius, J. (1983) Myeloid and megakaryocytic properties of K-562 cell lines. *Cancer research*, 43, 4569-4574. 76. Nakamura, M., Kirito, K., Yamanoi, J., Wainai, T., Nojiri, H. and Saito, M. (1991) Ganglioside GM3 can induce megakaryocytoid differentiation of human leukemia cell line K562 cells. *Cancer research*, 51, 1940-1945. 77. Andersson, L.C., Jokinen, M. and Gahmberg, C.G. (1979) Induction of erythroid differentiation in the human leukaemia cell line K562. *Nature*, 278, 364-365. 78. Andersson, L.C., Nilsson, K. and Gahmberg, C.G. (1979) K562--a human erythroleukemic cell line. *International journal of cancer. Journal international du cancer*, 23, 143-147. 79. Rutherford, T.R., Clegg, J.B. and Weatherall, D.J. (1979) K562 human leukaemic cells synthesise embryonic haemoglobin in response to haemin. *Nature*, 280, 164-165. 80. Lozzio, B.B., Lozzio, C.B., Bamberger, E.G. and Feliu, A.S. (1981) A multipotential leukemia cell line (K-562) of human origin. *Proceedings of the Society for Experimental Biology and Medicine*, 166, 546-550. 81. Traver, D., Miyamoto, T., Christensen, J., Iwasaki-Arai, J., Akashi, K. and Weissman, I.L. (2001) Fetal liver myelopoiesis occurs through distinct, prospectively isolatable progenitor subsets. *Blood*, 98, 627-635. 82. Yan, Q., Zhu, L., Kumar, N., Jiang, Z. and Huang, L. (2010) Characterisation of a novel monomeric lectin (AML) from *Astragalus membranaceus* with anti-proliferative activity. *Food Chemistry*, 122, 589-595. 83. Yang, M., Qian, X.H., Zhao, D.H. and Fu, S.Z. (2010) Effects of *Astragalus polysaccharide* on the erythroid lineage and microarray analysis in K562 cells. *Journal of ethnopharmacology*, 127, 242-250. 84. Donovan-Peluso, M., Acuto, S., Swanson, M., Dobkin, C. and Bank, A. (1987) Expression of human gamma-globin genes in human erythroleukemia (K562) cells. *The Journal of biological chemistry*, 262, 17051-17057. 85. Campbell, P.L., Kulozik, A.E., Woodham, J.P. and Jones, R.W. (1990) Induction by HMBA and DMSO of genes introduced into mouse erythroleukemia and other cell lines by transient transfection. *Genes & development*, 4, 1252-1266. 86. Yu, H., Lu, H., Zheng, B., Fan, H. and Xie, Y. (2002) Effect of hexamethylene bisacetamine on proliferation and apoptosis of human leukemia cells in vitro and relevant mechanisms. *Zhonghua yi xue za zhi*, 82, 549-552. 87. Dorsey, J.F., Cunnick, J.M., Mane, S.M. and Wu, J. (2002) Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2. *Blood*, 99, 1388-1397. 88. Peng, H.Y. and Liao, H.F. (2011) Staurosporine induces megakaryocytic differentiation through the upregulation of JAK/Stat3 signaling pathway. *Annals of hematology*, 90, 1017-1029. 89. Nelson, C.P., Rainbow, R.D., Brignell, J.L., Perry, M.D., Willets, J.M., Davies, N.W., Standen, N.B. and Challiss, R.A. (2011) Principal role of adenylyl cyclase 6 in K(+) channel regulation and vasodilator signalling in vascular smooth muscle cells. *Cardiovascular research*, 91, 694-702. 90. Sparatore, B., Passalacqua, M., Pessino, A., Melloni, E., Patrone, M. and Pontremoli, S. (1994) Modulation of the intracellular Ca(2+)-dependent proteolytic system is critically correlated with the kinetics of differentiation of murine erythroleukemia cells. *European journal of biochemistry / FEBS*, 225, 173-178. 91. Marks, P.A. and Rifkind, R.A. (1989) Induced differentiation of erythroleukemia cells by hexamethylene bisacetamide: a model for cytodifferentiation of transformed cells. *Environmental health perspectives*, 80, 181-188.